Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
08 Abril 2024 - 7:30AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced that it
will present at the Virtual Investor Lunch Break: The Team Behind
the AMIX Ticker event on Thursday, April 11, 2024 at 12:00 PM ET.
As part of the roundtable event, members of the
Autonomix management team including Lori Bisson, Chief Executive
Officer, Walter Klemp, Executive Chairman, Dr. Robert Schwartz,
Chief Medical Officer, Trent Smith, Chief Financial Officer,
Jennifer Cook, Chief Business Officer, and Marco Bedoya, Director
of Product Development, will provide introductions and describe the
important role they each play in achieving the Company’s common
goal. Additionally, interested parties will have the opportunity to
submit questions live. Management will answer as many questions as
possible during the event.
A live video webcast of the event will be
available on the Events page under the Investors section of the
Company’s website (autonomix.com). A webcast replay will be
available two hours following the live event and will be accessible
for 90 days.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Investor and Media Contact
JTC Team, LLCJenene Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Autonomix Medical (NASDAQ:AMIX)
Gráfica de Acción Histórica
De May 2023 a May 2024